Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Protara Therapeutics (TARA) Interest & Investment Income (2016 - 2026)

Protara Therapeutics' Interest & Investment Income history spans 12 years, with the latest figure at $1.7 million for Q1 2026.

  • Quarterly Interest & Investment Income rose 6.5% to $1.7 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $4.5 million through Mar 2026, up 10.71% year-over-year, with the annual reading at $5.0 million for FY2025, 51.02% up from the prior year.
  • Interest & Investment Income came in at $1.7 million for Q1 2026, up from $166000.0 in the prior quarter.
  • In the past five years, Interest & Investment Income ranged from a high of $1.7 million in Q1 2026 to a low of $119000.0 in Q1 2022.
  • The 5-year median for Interest & Investment Income is $820000.0 (2023), against an average of $827470.6.
  • Year-over-year, Interest & Investment Income soared 5020.0% in 2022 and then plummeted 62.07% in 2024.
  • Protara Therapeutics' Interest & Investment Income stood at $632000.0 in 2022, then grew by 29.75% to $820000.0 in 2023, then tumbled by 62.07% to $311000.0 in 2024, then crashed by 46.62% to $166000.0 in 2025, then surged by 897.59% to $1.7 million in 2026.
  • Per Business Quant, the three most recent readings for TARA's Interest & Investment Income are $1.7 million (Q1 2026), $166000.0 (Q4 2025), and $1.5 million (Q3 2025).